Alergologia Polska - Polish Journal of Allergology

Abstract

3/2022 vol. 9
Original paper

House dust mite sensitivity in atopic children with Dectin-1 rs7309123 polymorphism

  1. O.O. Bogomolets National Medical University, Kyiv, Ukraine
Alergologia Polska – Polish Journal of Allergology 2022; 9, 3: 191–195
Online publish date: 2022/09/07
View full text
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease

Introduction

Introduction: Sensitization to house dust mites is common in patients with atopic dermatitis. Dectin-1 polymorphism can affect the recognition of house dust mite allergens in the skin. Aim: To investigate the prevalence of sensitization to house dust mites in children with atopic dermatitis and the role of Dectin-1 rs7309123 polymorphism in the development of sensitivity to house dust mites.

Material and methods

The study included 101 patients with atopic dermatitis. Genotyping of the Dectin-1 rs7309123 was performed in the patient group using real-time PCR. Measurements of sIgE to dust mites were performed by Western blotting.

Results

Sensitization to house dust mites was found in 48.5% of the children. The presence of sIgE to HDM in patients with AD was significantly associated with concomitant allergic rhinitis (OR = 2.593 (1.096–6.133)) and in the group of children with both concomitant allergic diseases (OR = 7.432 (1.553–35.564)). There was statistically significant difference in the distribution of genotypes in patients with elevated serum IgE to HDM and among the children with normal levels (OR = 3.111 (0.924–10.480) for CC and GG; OR = 4.267 (1.432–12.716) for CG and GG).

Conclusions

The susceptibility to dust mites among children with atopic dermatitis is 48.5%. Dectin-1 is involved in the development of HDM-induced allergic inflammation in skin because polymorphism rs7309123 of the Dectin-1 gene may affect percutaneous sensitization to HDM in patients with AD, and the inhibition of signalling pathways of Dectin-1 may be an efficient therapeutic strategy.

Share
without publication fees